WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) will announce today at the 26th Annual JPMorgan Healthcare Conference further positive clinical proof-of-concept results for several of its wholly-owned, internally developed programs, including its JAK inhibitor for rheumatoid arthritis, myelofibrosis and psoriasis, as well as its 11-beta hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor for type 2 diabetes. During the JPMorgan presentation, the Company will also introduce its HM74a agonist program for type 2 diabetes and review the key objectives for all its lead programs in 2008.
